Abstracts tagged "Epigenetics"

Abstract Number: 2297 • 2012 ACR/ARHP Annual Meeting
Decrease Activity of DNA Demethylase in SSc Fibroblast and Microvascular Endothelial Cells: A Possible Mechanism for Persistence of SSc Phenotype
Bashar Kahaleh¹ and Yongqing Wang², ¹Medicine/Rheumatology, University of Toledo, Toledo, OH, ²Medicine, University of Toledo, Toledo, OH
Background/Purpose: DNA methylation is one of the best-characterized epigenetic modifications that have been implicated in numerous biologic and pathologic processes. It is initiated by DNA…
Abstract Number: 2270 • 2012 ACR/ARHP Annual Meeting
The DNA Methylome of Systemic Lupus Erythematosus (SLE) From Whole Peripheral Blood Mononuclear Cells (PBMCs)
Robert Shoemaker¹, Lou H. Bookbinder², David L. Boyle³, Gary S. Firestein⁴, Jonathan E. Lim⁵ and David W. Anderson⁶, ¹Bioinformatics, NexDx, Inc., San Diego, CA, ²Molecular Biology, NexDx, Inc., San Diego, ³Div of Rheum, UCSD School of Medicine, La Jolla, CA, ⁴Div of Rheumatology, UCSD School of Medicine, La Jolla, CA, ⁵Research and Development, NexDx, Inc., San Diego, ⁶Research and Development, NexDx, Inc., San Diego, CA
Background/Purpose: SLE is a disease where epigenetic mechanisms play a role. Methylation of DNA at CpG loci is known to influence the suppression or activation…
Abstract Number: 1610 • 2012 ACR/ARHP Annual Meeting
The DNA Methylation Signature in Fibroblast-Like Synoviocytes (FLS) Defines Critical Pathogenic Pathways in Rheumatoid Arthritis (RA)
David L. Boyle¹, Robert Shoemaker², David W. Anderson³, Wei Wang⁴ and Gary S. Firestein⁵, ¹Div of Rheum, UCSD School of Medicine, La Jolla, CA, ²NexDx, Inc., San Diego, CA, ³Research and Development, NexDx, Inc., San Diego, CA, ⁴Chemistry, UCSD, La Jolla, CA, ⁵Div of Rheumatology, UCSD School of Medicine, La Jolla, CA
Background/Purpose: A DNA methylation signature has been characterized that distinguishes RA FLS from osteoarthritis (OA) and normal (NL) FLS. The presence of epigenetic changes in…
Abstract Number: 985 • 2012 ACR/ARHP Annual Meeting
Inverse Relation Between the tumor Necrosis Factor Promoter Methylation and Trascript Leveles in Leukocytes From Patients with Rheumatoid Arthritis
James R. Maxwell¹, Lyndsey H. Taylor², Richardo A. Pachecho², Neil Lawrence², Gordon W. Duff³, M. Dawn. Teare² and Anthony G. Wilson⁴, ¹University of Sheffield, Sheffield, United Kingdom, ²University of Sheffield, United Kingdom, ³Royal Hallamshire Hospital, Sheffield, United Kingdom, ⁴Infection and Immunity, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: The importance of the epigenetic signature in RA is unclear but levels of methylation of CpG motifs in the TNF promoter are known to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.